measles virus vaccine, live, attenuated (Attenuvax)
Jump to navigation
Jump to search
Epidemiology
- small decline in vaccination rate could triple number of measles cases[3]
Indications
- immunization against measles (rubeola) in patients > 15 months of age
Contraindications
- hypersensitivity to eggs
- hypersensitivity to neomycin
- pregnancy
Caution:
- history of febrile seizures
- females should avoid pregnancy for 3 months afer vaccination
- defer vaccination for 3 months following plasma transfusions or administration of immune globulin or immunosuppressive drugs
Dosage
Children > 15 months & adults: 0.5 mL SC
Injection: 1000 TCID50 per dose
Adverse effects
- common (> 10%)
- less common (1-10%)
- fever 100-103 F, delayed-type allergic reaction
- uncommon (< 1%)
- difficulty breathing, hives, itching, reddening of skin (especially around eyes & ears), tiredness, convulsions, encephalitis, confusion, severe headache, stiff neck, vomiting, diplopia, thrombocytopenic purpura, prolonged fever > 103 F, lymphadenopathy
- risk of fever & seizures greater at age 16-18 months than at 12-15 months[2] Drug interations:
Vaccine interactions:
- should not be given within 1 month of other live virus vaccines except monovalent or trivalent polio vaccine
Test interactions
- temporary suppression of TB skin test reactivity
More general terms
Additional terms
- measles & rubella combined vaccine (M-R-VAX II)
- measles (1st disease)
- measles virus (rubeola)
- measles, mumps & rubella combined vaccine (MMR)
Component of
- measles virus vaccine live attenuated/mumps virus vaccine/rubella virus vaccine live
- measles virus vaccine live attenuated/mumps virus vaccine/rubella virus vaccine live/varicella virus vaccine
- measles virus vaccine live attenuated/rubella virus vaccine live
References
- ↑ Kaiser Permanente Northern California Regional Drug Formulary, 1998
- ↑ 2.0 2.1 Rowhani-Rahbar A et al. Effect of age on the risk of fever and seizures following immunization with measles-containing vaccines in children. JAMA Pediatr 2013 Oct 14 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/24126936 <Internet> http://archpedi.jamanetwork.com/article.aspx?articleid=1750204
Feemster KA and Offit P. Delaying vaccination is not a safer choice. JAMA Pediatr 2013 Oct 14 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/24126848 <Internet> http://archpedi.jamanetwork.com/article.aspx?articleid=1750202 - ↑ 3.0 3.1 Lo NC, Hotez PJ Public Health and Economic Consequences of Vaccine Hesitancy for Measles in the United States. JAMA Pediatr. Published online July 24, 2017 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/28738137 <Internet> http://jamanetwork.com/journals/jamapediatrics/fullarticle/2643169